Xytis, Inc.

Xytis to Initiate First-In-Class Phase I Clinical Trials with Alpha 7 Nicotinic Acetylcholine Receptor Positive Allosteric Modulator XY4083

Published in Mental Health Weekly Digest, December 1st, 2008

Xytis, Inc. announced it has received permission from the FDA to conduct Phase I single and multiple ascending dose studies with its novel positive allosteric modulator, XY4083. Xytis plans to begin these studies in early 2009.

"Allosteric modulation is the safest and most natural way to enhance the activity of a neuroreceptor," stated Vincent F. Simmon, Ph.D., President and CEO of Xytis. "There are two alternatives for enhancing activity of a neuroreceptor; binding at the normal ligand binding site, or binding at a distant site. Classically, direct agonist drugs bind to the neurotransmitter binding site and provide a constant, but non-physiological, activated receptor....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Weekly Digest

Source: Mental Health Weekly Digest (2008-12-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry